Multiple sclerosis trials recruiting in Tennessee

All Multiple sclerosis trials nationally

Cities in Tennessee

Recruiting trials in Tennessee

• A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
  NCT06143514 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · Tennessee: Nashville
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Franklin, Knoxville, Mount Juliet, Nashville
• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
  NCT07609719 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Cordova
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Tennessee: Cordova
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Tennessee: Cordova
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Cordova
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
  NCT06782490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Tennessee: Knoxville
• AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  NCT06665165 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville
• Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
  NCT06441617 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · Tennessee: Knoxville
• Familial Investigations of Childhood Cancer Predisposition
  NCT03050268 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Tennessee: Knoxville
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Tennessee: Knoxville
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Knoxville
• TSC Biosample Repository and Natural History Database
  NCT05676099 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis